Companion diagnostics (CDx)

Tissue-based companion diagnostics market to grow for the most common cancers in China

Companion diagnostics (CDx) use is growing as the cancer treatment paradigm-shifts towards immunotherapy and targeted therapy.

In 2020, China accounted for almost a quarter of the world’s newly-diagnosed cancer cases and 30% of cancer-related deaths. Lung cancer is the most common cancer type and the leading cause of cancer death, while breast cancer is the most common type among women.

China has improved access to targeted therapies for the most prevalent cancer types, by including targeted therapies for HER2-positive breast cancer and ALK-positive lung cancer in the national reimbursement list. 

The broadened access to targeted treatment has driven up the demand for immunohistochemistry (IHC) testing. Economist Intelligence Clearstate expects the market for IHC reagents to grow 10% annually on average in the forecast period of 2019-2024 as cancer cases continue to rise. Local clinical guidelines have made HER2 testing a necessity in breast cancer diagnosis, with IHC performed as a first-line test. Routine IHC screening is used to detect the ALK biomarker in lung cancer cases. 

For more on the tissue diagnostics (TDx) market, download the briefing paper on Cancer and the tissue diagnostics market outlook

IVD Gateway: IVD Market and Forecasts with Covid-19 Impact

The go-to-source for Covid-19 impact on In-Vitro Diagnostics test demand in 2020 and market recovery trends in 2021 for all 130+ IVD test segments across countries in Asia, Europe and Latin America.